Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Alkylator-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Lymphoma: A Registry Study Comparing Thiotepa-, Busulfan-, Melphalan- and Treosulfan-Containing Regimens On Behalf of the EBMT Lymphoma Working Party

Peter Dreger, MD, Herve Finel, Renato Fanin, MD, Paolo Corradini, MD, Michele Falda, MD, Jürgen Finke, MD, William Arcese, MD, Piero Galieni, MD, Luca Castagna, MD, Domenico Russo, Mats L Brune, Rosanna Scimè, MD, Enrico Maria Pogliani, MD, Fabio Benedetti, MD, Norbert Schmitz, MD, Ariane Boumendil

Blood (2012) 120 (21): 2033.

DOI: https://doi.org/10.1182/blood.V120.21.2033.2033

Published: 2012

Journal Articles

Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg

Blood (2012) 120 (21): 302.

DOI: https://doi.org/10.1182/blood.V120.21.302.302

Published: 2012

Journal Articles

Prognostic Impact of Recipient and Donor CMV Serostatus in Acute Leukemia Patients After Allogeneic Stem Cell Transplantation At the Era of Preemptive Therapy.

Martin Schmidt-Hieber, Myriam Labopin, Dietrich Beelen, Liisa Volin, Gerhard Ehninger, Jürgen Finke, Gerard Socie, Rainer Schwerdtfeger, Nicolaus Kröger, Arnold Ganser, Dietger Niederwieser, Ulrike Feldmann, Carlheinz Müller, Emanuelle Polge, Igor Wolfgang Blau, Mohamad Mohty

Blood (2012) 120 (21): 3110.

DOI: https://doi.org/10.1182/blood.V120.21.3110.3110

Published: 2012

Journal Articles

Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantaion - a Multicenter Retrospective Analysis

Elisabeth Schorb, MD, Benjamin Kasenda, MD, Johannes Atta, Nikolas von Bubnoff, MD, Thomas Elter, MD, Georg Hess, Stefan W. Krause, MD, Anke Morgner, Kaun Stephan, Kristina Fritsch, MD, Jürgen Finke, MD, Gerald Illerhaus

Blood (2011) 118 (21): 3089.

DOI: https://doi.org/10.1182/blood.V118.21.3089.3089

Published: 2011

Journal Articles

Prognostic Pre-Transplant Factors in Myelodysplastic Syndromes Primarily Treated by Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study on Behalf of the MDS Subcommittee of the Chronic Leukaemia Working Party of the EBMT

Eline Cremers, Anja van Biezen, StatAnalyst, Liesbeth C. de Wreede, PhD, Marijke Scholten, Antonin Vitek, Jürgen Finke, Uwe Platzbecker, MD, Dietrich Beelen, Rainer Schwerdtfeger, Liisa Volin, Nikolaos Harhalakis, Anton Schattenberg, Arnon Nagler, Theo de Witte, MD, PhD, Nicolaus Kröger

Blood (2011) 118 (21): 3014.

DOI: https://doi.org/10.1182/blood.V118.21.3014.3014

Published: 2011

Journal Articles

Early Lenalidomide Maintenance to Prevent Relapse of High-Risk MDS and AML Patients with Del(5q) Following Allogeneic HCT - Results of the “LENAMAINT” Trial

Katja Sockel, MD, Jochen Greiner, MD, Rudolf Trenschel, MD, Christian Unzicker, MD, Guido Kobbe, MD, Jürgen Finke, MD, Ulrich Germing, MD, Brigitte Mohr, Dietrich Beelen, Gerhard Ehninger, MD, Martin Bornhaeuser, Uwe Platzbecker, MD

Blood (2011) 118 (21): 3060.

DOI: https://doi.org/10.1182/blood.V118.21.3060.3060

Published: 2011

Journal Articles

Busulfan (Bu) Plus Cyclophosphamide (Cy) Versus TBI Plus Cy Conditioning for Allogeneic Stem Cell Transplantation (alloSCT) From Matched Unrelated Donors (MUD) In Adult Patients with AML in First Relapse: A Survey From the Acute Leukemia Working Party of EBMT

Arnon Nagler, MD, Myriam Labopin, MD, MS, Avichai Shimoni, MD, Jürgen Finke, MD, Dietrich Beelen, Liisa Volin, Jakob R. Passweg, MD, Rainer Schwerdtfeger, Hans-Jochem Kolb, MD, Achilles Anagnostopoulos, MD, Vanderson Rocha, MD, PhD, Fabio Ciceri, MD, Mohamad Mohty

Blood (2011) 118 (21): 161.

DOI: https://doi.org/10.1182/blood.V118.21.161.161

Published: 2011

Journal Articles

FDG-PET Is An Independent Predictor for Survival in Primary Central Nervous System Lymphoma

Benjamin Kasenda, MD, Vanessa Haug, Elisabeth Schorb, MD, Kristina Fritsch, MD, Wolfgang Weber, MD, Jürgen Finke, MD, Gerald Illerhaus, MD, Philipp T Meyer, MD

Blood (2011) 118 (21): 2687.

DOI: https://doi.org/10.1182/blood.V118.21.2687.2687

Published: 2011

Journal Articles

Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network ( MCL net )

Blood (2010) 116 (21): 110.

DOI: https://doi.org/10.1182/blood.V116.21.110.110

Published: 2010

Journal Articles

Everolimus Enhances Immunomodulation of Alloreative T Cells by Multipotent Stromal Cells Due to Transforming Growth Factor - β Dependent Mechanisms

Razvan George Racila, Wolfgang Melchinger, Jürgen Finke, MD, Reinhard E Marks

Blood (2010) 116 (21): 2545.

DOI: https://doi.org/10.1182/blood.V116.21.2545.2545

Published: 2010

Journal Articles

Immuno-Chemotherapy with Rituximab, Methotrexate, Lomustine, and Procarbazine for the Treatment of Primary CNS Lymphoma in Patients >65 Years.

Kristina Fritsch, Benjamin Kasenda, Anna Markert, Jürgen Finke, Gerald Illerhaus

Blood (2009) 114 (22): 3712.

DOI: https://doi.org/10.1182/blood.V114.22.3712.3712

Published: 2009

Journal Articles

Tissue Damage and Lymphoma Derived Chemoattractive Signals Impact Regulatory T Cell Trafficking After Allogeneic Hematopoietic Cell Transplantation.

Christoph Dürr, Dietmar Pfeifer, PhD, Annette Schmitt-Gräff, Rainer Claus, Ulrike Gerlach, Ralph Graeser, Armin Gerbitz, MD, Robert Negrin, Jürgen Finke, Robert Zeiser, MD

Blood (2009) 114 (22): 3564.

DOI: https://doi.org/10.1182/blood.V114.22.3564.3564

Published: 2009

Journal Articles

Comparison of Outcomes After Unrelated Cord Blood Transplantation and Matched Unrelated Donor RIC Transplantation for Lymphoid Malignancies - A Eurocord-Netcord Group/ Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study.

Blood (2009) 114 (22): 663.

DOI: https://doi.org/10.1182/blood.V114.22.663.663

Published: 2009

Journal Articles

Allogeneic Stem Cell Transplantation for Acquired Aplastic Anemia: Better Outcome with Bone Marrow as Compared to Peripheral Blood in HLA-Matched Sibling Donor Transplantation and Improved Outcome Over Time After Matched Unrelated Donor Transplantation. A Retrospective Analysis of Transplants Reported to the German Registry for Stem Cell Transplantation (DRST).

Hubert Schrezenmeier, Ulrike Feldmann, Hellmut Ottinger, Matthias Eder, Monika Führer, Hans-Jochem Kolb, Axel Zander, Karin Kolbe, Dietger Niederwieser, Donald W. Bunjes, MD, PhD, Rainer Schwerdtfeger, MD, Rupert Handgretinger, Karl Welte, Carlheinz Müller, Gerhard Ehninger, Jürgen Finke, Dietrich Beelen

Blood (2009) 114 (22): 876.

DOI: https://doi.org/10.1182/blood.V114.22.876.876

Published: 2009

Journal Articles

Mathematical Modeling in Optimizing Methotrexate-Based Chemotherapy.

Benjamin Kasenda, Marcel Rehberg, Melanie Franzem, Kristina Fritsch, Anna Markert, Jürgen Finke, Dirk Lebiedz, Gerald Illerhaus

Blood (2009) 114 (22): 4766.

DOI: https://doi.org/10.1182/blood.V114.22.4766.4766

Published: 2009

Journal Articles

Supportive Care Only Versus Allogeneic Hematopoietic Cell Transplantation in Patients ≥ 60 Years with De Novo High-Risk MDS.

Uwe Platzbecker, Jürgen Finke, Rudolf Trenschel, Schaefer-Eckart Kerstin, Martin Bornhauser, Guido Kobbe, Bart L Scott, Gerhard Ehninger, Dietrich Beelen, H. J. Deeg, Ulrich Germing

Blood (2009) 114 (22): 596.

DOI: https://doi.org/10.1182/blood.V114.22.596.596

Published: 2009

Journal Articles

ATP Acts as Danger Associated Molecular Pattern and Enhances Acute Graft-Versus-Host Disease Severity Via P2×7-R.

Konrad Wilhelm, Tobias Müller, Jayanthi Ganesan, Christoph Dürr, Ulrike Gerlach, Alf Zerweck, Jürgen Finke, Marco Idzko, Robert Zeiser, MD

Blood (2009) 114 (22): 1336.

DOI: https://doi.org/10.1182/blood.V114.22.1336.1336

Published: 2009

Journal Articles

Low Incidence of Pulmonary Graft-Versus-Host Disease in Older Patients After Reduced Toxicity Conditioning with FBM Prior to Hematopoietic Stem Cell Transplantation.

Jesus Duque-Afonso, Antje Prasse, Ralph M. Waesch, Hartmut Bertz, Jürgen Finke, Reinhard Marks

Blood (2009) 114 (22): 4660.

DOI: https://doi.org/10.1182/blood.V114.22.4660.4660

Published: 2009

Journal Articles

GvHD Prophylaxis with Everolimus and Mycophenolate in Allogeneic Hematopoietic Cell Transplantation - A Phase I/II Study.

Reinhard Marks, Alf Zerweck, Razvan George Racila, Hartmut Bertz, Jürgen Finke

Blood (2009) 114 (22): 4642.

DOI: https://doi.org/10.1182/blood.V114.22.4642.4642

Published: 2009

Journal Articles

Alloantigeneic Reactions after Human Hematopoietic Cell Transplantation Induce Genomic Alterations in Epithelium: A Confirmation in Vivo and in Vitro Study and Implications to Secondary Neoplasia

Maria Themeli, Loizos Petrikkos, Miguel Waterhouse, Hartmut Bertz, Eleni Lagadinou, Nicholas Zoumbos, Jürgen Finke, Alexandros Spyridonidis

Blood (2008) 112 (11): 452.

DOI: https://doi.org/10.1182/blood.V112.11.452.452

Published: 2008

NARROW

Alkylator-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Lymphoma: A Registry Study Comparing Thiotepa-, Busulfan-, Melphalan- and Treosulfan-Containing Regimens On Behalf of the EBMT Lymphoma Working Party

Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg

Prognostic Impact of Recipient and Donor CMV Serostatus in Acute Leukemia Patients After Allogeneic Stem Cell Transplantation At the Era of Preemptive Therapy.

Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantaion - a Multicenter Retrospective Analysis

Prognostic Pre-Transplant Factors in Myelodysplastic Syndromes Primarily Treated by Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study on Behalf of the MDS Subcommittee of the Chronic Leukaemia Working Party of the EBMT

Early Lenalidomide Maintenance to Prevent Relapse of High-Risk MDS and AML Patients with Del(5q) Following Allogeneic HCT - Results of the “LENAMAINT” Trial

Busulfan (Bu) Plus Cyclophosphamide (Cy) Versus TBI Plus Cy Conditioning for Allogeneic Stem Cell Transplantation (alloSCT) From Matched Unrelated Donors (MUD) In Adult Patients with AML in First Relapse: A Survey From the Acute Leukemia Working Party of EBMT

FDG-PET Is An Independent Predictor for Survival in Primary Central Nervous System Lymphoma

Everolimus Enhances Immunomodulation of Alloreative T Cells by Multipotent Stromal Cells Due to Transforming Growth Factor - β Dependent Mechanisms

Immuno-Chemotherapy with Rituximab, Methotrexate, Lomustine, and Procarbazine for the Treatment of Primary CNS Lymphoma in Patients >65 Years.

Tissue Damage and Lymphoma Derived Chemoattractive Signals Impact Regulatory T Cell Trafficking After Allogeneic Hematopoietic Cell Transplantation.

Comparison of Outcomes After Unrelated Cord Blood Transplantation and Matched Unrelated Donor RIC Transplantation for Lymphoid Malignancies - A Eurocord-Netcord Group/ Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study.

Mathematical Modeling in Optimizing Methotrexate-Based Chemotherapy.

Supportive Care Only Versus Allogeneic Hematopoietic Cell Transplantation in Patients ≥ 60 Years with De Novo High-Risk MDS.

ATP Acts as Danger Associated Molecular Pattern and Enhances Acute Graft-Versus-Host Disease Severity Via P2×7-R.

Low Incidence of Pulmonary Graft-Versus-Host Disease in Older Patients After Reduced Toxicity Conditioning with FBM Prior to Hematopoietic Stem Cell Transplantation.

GvHD Prophylaxis with Everolimus and Mycophenolate in Allogeneic Hematopoietic Cell Transplantation - A Phase I/II Study.

Alloantigeneic Reactions after Human Hematopoietic Cell Transplantation Induce Genomic Alterations in Epithelium: A Confirmation in Vivo and in Vitro Study and Implications to Secondary Neoplasia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only